We are live on
!
Find out more
AC
Armistice Capital Portfolio holdings
AUM
$5.62B
1-Year Est. Return
36.06%
This Fund
S&P 500
This Quarter
Est. Return
+13.99%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$7.33B
AUM Growth
+$796M
(+12%)
Cap. Flow
-$12M
Cap. Flow
% of AUM
-0.16%
Top 10 Holdings %
Top 10 Hldgs %
60.07%
Holding
377
New
123
Increased
61
Reduced
77
Closed
82
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GSK
GSK
|
+$68.6M |
| 2 |
argenx
ARGX
|
+$55M |
| 3 |
Sanofi
SNY
|
+$50.7M |
| 4 |
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
|
+$50.5M |
| 5 |
Jazz Pharmaceuticals
JAZZ
|
+$42.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$48.6M |
| 2 |
Keurig Dr Pepper
KDP
|
+$45.5M |
| 3 |
Incyte
INCY
|
+$45.2M |
| 4 |
UnitedHealth
UNH
|
+$37.3M |
| 5 |
Campbell Soup
CPB
|
+$32M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 34.97% |
| 2 | Consumer Staples | 5.35% |
| 3 | Consumer Discretionary | 4.92% |
| 4 | Technology | 3.86% |
| 5 | Communication Services | 1.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
PENN Entertainment
PENN
$2.7B
| $241K | ﹤0.01% |
+9,249
| New | +$215K |
|
227
Sherwin-Williams
SHW
$89.7B
| $240K | ﹤0.01% |
+771
| New | +$207K |
|
|
TCBP
228
DELISTED
TC BioPharm (Holdings) plc American Depositary Shares
TCBP
| $235K | ﹤0.01% |
463
+370
| +398% | +$417K |
|
|
GRMN
229
Garmin
GRMN
$59.2B
| $225K | ﹤0.01% |
+1,754
| New | +$203K |
|
230
Verizon
VZ
$193B
| $220K | ﹤0.01% |
+5,825
| New | +$206K |
|
231
My Size
MYSZ
$1.75M
| $213K | ﹤0.01% |
39,375
+17,250
| +78% | +$100K |
|
|
AGRX
232
DELISTED
Agile Therapeutics
AGRX
| $211K | ﹤0.01% |
108,000
+10,000
| +10% | +$20.1K |
|
233
Heartbeam Inc Warrant
BEATW
| $200K | ﹤0.01% |
500,000
| – | – |
|
234
Telus
TU
$15.6B
| $199K | ﹤0.01% |
11,202
+377
| +3% | +$6.52K |
|
235
Sportradar
SRAD
$3.77B
| $199K | ﹤0.01% |
+18,034
| New | +$177K |
|
|
APCX
236
DELISTED
AppTech Payments
APCX
| $199K | ﹤0.01% |
+100,000
| New | +$211K |
|
237
SLM Corp
SLM
$5.16B
| $198K | ﹤0.01% |
+10,363
| New | +$156K |
|
238
QuantumScape Corp
QS
$3.56B
| $198K | ﹤0.01% |
+28,488
| New | +$179K |
|
|
BKYI
239
BIO-key International
BKYI
$4.49M
| $196K | ﹤0.01% |
+6,533
| New | +$285K |
|
240
SoFi Technologies
SOFI
$23.9B
| $185K | ﹤0.01% |
+18,594
| New | +$148K |
|
241
OR Royalties Inc
OR
$6.22B
| $184K | ﹤0.01% |
+12,859
| New | +$169K |
|
242
Netcapital
NCPL
$3.22M
| $182K | ﹤0.01% |
+12,286
| New | +$307K |
|
243
Virax Biolabs
VRAX
$2.23M
| $178K | ﹤0.01% |
+4,880
| New | +$285K |
|
244
Krispy Kreme
DNUT
$578M
| $170K | ﹤0.01% |
+11,282
| New | +$149K |
|
|
SKYAW
245
SkyAI Inc
SKYAW
$263K
| $159K | ﹤0.01% |
1,176,000
| – | – |
|
246
Greenlane Holdings
GNLN
$1.24M
| $156K | ﹤0.01% |
5
| – | – |
|
247
CNS Pharmaceuticals
CNSP
$7.8M
| $155K | ﹤0.01% |
+4
| New | +$209K |
|
|
MOTS
248
DELISTED
Motus GI Holdings, Inc. Common Stock
MOTS
| $152K | ﹤0.01% |
119,000
+81,200
| +215% | +$408K |
|
|
SDEV
249
Stablecoin Development Corp
SDEV
$52M
| $147K | ﹤0.01% |
+4,107
| New | +$234K |
|
|
SCNI
250
Scinai Immunotherapeutics
SCNI
$1.31M
| $137K | ﹤0.01% |
23,090
-13,155
| -36% | -$90.5K |
|
Similar funds
CRC
RMDI
F
EW
O
DSC
ACM
PI
Armistice Capital's Q4 2023 Portfolio in Review
As of Q4 2023, Armistice Capital held 377 positions worth $7.33B, up 12% from $6.53B the previous quarter. Its ten largest holdings account for 60% of the portfolio.
Armistice Capital's Q4 2023 filing shows 123 new, 61 increased, 77 reduced and 82 closed positions. Its largest new stake was Sanofi: 1,036,000 shares worth $51.5M. The largest sale was Mirati Therapeutics, Inc. Common Stock, an estimated $48.6M.
By sector, the portfolio is most concentrated in Healthcare at 35% of assets, up from 34% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.
- Armistice Capital's largest Q4 2023 buy was Sanofi: 1,036,000 shares worth $51.5M.
- Armistice Capital added most to GSK in Q4 2023, an estimated $68.6M increase.
- Armistice Capital's biggest Q4 2023 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $48.6M.
- Armistice Capital fully exited Keurig Dr Pepper in Q4 2023, selling an estimated $45.5M.
- Armistice Capital's ten largest holdings make up 60% of its $7.33B portfolio in Q4 2023.
- Armistice Capital opened 123 new positions and closed 82 in Q4 2023.
- Armistice Capital's portfolio value rose 12% quarter-over-quarter to $7.33B.
Based on Armistice Capital's 13F filing for Q4 2023, filed 13 Feb 2024.